Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: PRRT with radiolabelled SSTR agonists is highly effective and has become an integral part of NET treatment. Tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. DOTA-JR11 (OPS201) is a very promising next-generation SSTR2-selective antagonist.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Nicolas G, Baum R, Herrmann K, Lassmann M, Hicks R,
Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: kong G
Authors: Kong G, Grozinsky-Glasberg S, Callahan J, Hofman M, Meirovitz A,
Keywords: PRRT,
Introduction: PH & PG are rare neuroendocrine tumors treated with MIBG but protocols are not standardized and reported results are variable.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Salih Z, Fletcher K, Clay V, Manoharan P, Hawkins R,
Keywords: mibg,
Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Nastos K, Toumpanakis C, Cheung V, Navalkissoor S, Quigley A,
Keywords: paraganglioma, pheochromocytoma, (131)I-MIBG, PRRT,
Introduction: The current study explores novel targeted therapies for malignant pheochromocytomas (PCCs) and paragangliomas, utilizing a more benign (MPC) and a more malignant (MTT) PCC cell line. We have previously shown that the dual PI3K/mTORC1 inhibitor NVP-BEZ235 significantly reduced MPC and MTT cell viability, but increased ERK signalling.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Noelting S, Garcia E, Alusi G, Korbonits M, Grossman A,
Keywords: pheochromocytoma, cell lines, proliferation, MAPK, mTOR,